Is Natera Inc. (NASDAQ:NTRA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Natera Inc. at current levels.
Signatera is becoming the standard of care in cancer monitoring, and Natera owns the category before competitors have a real answer.
Where NTRA is headed
By the end of 2027, Signatera will likely be running at over 1 million tests per year, up from roughly 500,000 in 2025. That alone changes what Natera is. It stops being a women's health company that happens to sell a cancer test and becomes an oncology infrastructure business with a prenatal franchise attached. The shift matters because Medicare reimbursement for Signatera in colorectal, breast, and immunotherapy monitoring is now setting the template for private payers, and every quarter of clinical evidence (the GALAXY data, the BESPOKE CRC readout, the CIRCULATE trials) makes it harder for an oncologist to NOT order the test. When a diagnostic crosses from useful to medico-legally expected, the volume curve goes vertical.
Read the full Compass Direction on NTRA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios.
See the full NTRA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Natera Inc. (NASDAQ:NTRA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Natera Inc. at current levels. Signatera is becoming the standard of care in cancer monitoring, and Natera owns the category before competitors have a real answer.
What is NTRA's Compass Score?
Natera Inc. scores 49/100 on Alexandria's Compass, placing it in the "Neutral" tier. Scores blend eight factors and update weekly.
What is the price target for NTRA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the NTRA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.